TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03759119

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tummy time and parent education
Description: Participants will receive tummy time positioning while awake for 10 minutes two times a day. Physiological monitoring will be maintained throughout the entire intervention and the intervention will be adjusted if needed to maintain stability. Participants will also receive parent education on tummy time prior to the tummy time intervention. The primary investigator will perform the tummy time intervention. Participants will be encouraged to continue performing tummy time on their own and record their adherence via the PT Pal application.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent education only
Description: Participants will receive the same tummy time education as those in the intervention group and will be asked to continue the intervention on their own and record their adherence via the PT Pal application.~Steps of the intervention for group 2 (standard care).~* Complete educational session with primary investigator.~* Adherence during the four-week intervention period will be measured remotely through the PT Pal® application.
Study: NCT03388489

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-Body Walking
Description: walking, breathing, and mindfulness
Study: NCT04502589

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perampanel Tablet
Description: Subjects will be titrated over 3 weeks to a target dose of 8mg perampanel daily in both groups

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Disulfiram
Description: Disulfiram will be kept at 250mg daily
Study: NCT01471236

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Agili-C Bi-phasic Implant
Description: The implantation site should be created in perpendicular manner to the articular cartilage. The surrounding tissue will be cleaned and scraped to prepare a clean site. The implant will be placed in the correct orientation (drilled channels pointing towards the joint side and chamfer towards the bone).~The implant will be inserted gently in a pressed fit manner.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mini-arthrotomy
Description: The procedure will be conducted according to hospital practice. The implants will be positioned via open incision, depending on lesion location, and Investigator's final decision. Related treatments during the procedure should be recorded.~Device positioning details medications and adverse events during the procedure will be recorded. MOCART (off-site), X-ray evaluation (off-site), ICRS Cartilage injury mapping system, Articular cartilage injury Classification and the Osteochondritis Dissecans classification will be recorded.
Study: NCT01804283

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ischemic postconditioning
Description: multiple brief ischemic-reperfusion episodes immediately after sustained ischemic insult~Postconditioning was started at 30 s after aortic cross declamping, and the aorta was re-clamped for 30 s rendering global myocardial ischemia. Meanwhile aortic root suction was established during aortic re-clamping, and thereafter, the aortic clamp was released for 30 s for full myocardial reperfusion. The cycle was repeated three times after cardioplegic arrest.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: double valve replacement
Description: The double valve replacement is a procedure in which surgery is used to replace diseased aortic and mitral heart valves.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: double valve replacement
Description: The double valve replacement is a procedure in which surgery is used to replace diseased aortic and mitral heart valves.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: heart-lung machine
Description: The heart-lung machine is commonly used in open heart surgery including double valve replacement to support the circulation during the operation.
Study: NCT01251315

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N Acetyl cysteine, 1200mg (high dose)
Description: N Acetyl cysteine (high dose) N-Acetyl Cysteine(NAC)1200mg (high dose) given as a single dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FT061452, 6000mg high dose
Description: Proimmune 200(FT061452) high dose group given 6000 mg as a single dose.
Study: NCT04402385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg
Description: Participants randomized to 81 mg of Aspirin daily
Study: NCT00062985

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mail-based weight loss intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone-based weight loss intervention
Study: NCT01329900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: 1000 mg by vein on Day 1 and 2000 mg by vein on Day 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: 3.33 gm/m2 by vein on Days 2, 3, and 4 continuously.
Study: NCT04402385

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to placebo daily
Study: NCT04692896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Description: different concentrations of lidocaine with same concentration of adrenaline
Study: NCT01804283

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: heart-lung machine
Description: The heart-lung machine is commonly used in open heart surgery including double valve replacement to support the circulation during the operation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Aortic cross-clamp
Description: a surgical instrument used in cardiac surgery to clamp the aorta
Study: NCT01804283

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aortic cross-clamp
Description: a surgical instrument used in cardiac surgery to clamp the aorta
Study: NCT01606436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023
Description: Administered orally.
Study: NCT04249284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165 prototype 1
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165 prototype 2
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165 prototype 2
Description: Specified dose on specified days
Study: NCT03822780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquin
Description: Hydroxychloroquine Sulfate (HCQ, Quensyl) in a loading dose of 10 mg/kg\*d, p.o., bid. After the illness gradually alleviate to maintain dose between 5mg/kg\*d to 10mg/kg\*d, p.o., bid ; the maximum daily dose is 400mg.
Study: NCT01017666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB014
Description: BIIB014 100mg PO Cohort 1 - 8d Cohort 2 - 14d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB014
Description: BIIB014 100mg PO Cohort 1 - 8d Cohort 2 - 14d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched placebo to BIIB014 Cohort 1 - 8d Cohort 2 - 14d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched placebo to BIIB014 Cohort 1 - 8d Cohort 2 - 14d
Study: NCT02170558

Intervention type: DEVICE
Intervention: TM- Ardis implant and Metal Reduction CT software
Description: TM- Ardis implant and Metal Reduction CT software
Study: NCT01129414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: matching tablet~Route of administration: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: matching tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Pharmaceutical form: delayed-release capsule~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Pharmaceutical form: delayed-release capsule~Route of administration: oral
Study: NCT01329900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 150 mg/m2 by vein over 2 hours every 12 hours Days 2, 3, and 4 for 6 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: 2 gm/m2 by vein over 1 hour on Day 2 (given before Ifosfamide starts)~2.66 gm/m2/day by vein continuous infusion given over 24 hours daily for 3 days starting on Day 2 (together with Ifosfamide)~After Ifosfamide/Mesna, 2 gm/m2 by vein given over 12 hours for one dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 6 mcg/kg subcutaneously twice a day on day 6 (rounded off to the nearest vial) until completion of apheresis.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Collection
Description: Blood stem cells will be collected when blood counts have returned to normal (about 10-16 days after chemotherapy). Stem cell collection takes about 4 hours each time.
Study: NCT01025115

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diamel
Description: Two Diamel tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 12 months, together with the standard treatment for metabolic syndrome consisting in appropriate diet according to patient's weight and physical activity, and appropriate hypertensive drugs (generally ACE inhibitors) for hypertension. Patient´s were also verbally encouraged to increase physical activity (to walk for 30-45 minutes a day 3-4 days a week).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two Placebo tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 12 months, together with the standard treatment for metabolic syndrome consisting in appropriate diet according to patient's weight and physical activity, and appropriate hypertensive drugs (generally ACE inhibitors) for hypertension. Patient´s were also verbally encouraged to increase physical activity (to walk for 30-45 minutes a day 3-4 days a week).
Study: NCT01606436

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: OTHER
Intervention: Moxifloxacin
Description: Administered orally.
Study: NCT02742610

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness with Contingency Management

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Study: NCT02658929

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bb2121
Description: bb2121
Study: NCT05123261

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the mindfulness-based elder care (MBEC) therapy
Description: According to the mindfulness-based elder care (MBEC) therapy developed by McBee (2008), the experimental group was offered eight 50-minute courses once a week.
Study: NCT02984748

Intervention type: DEVICE
Intervention: Cochlear implant
Study: NCT02003820

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: video modeled social story
Description: Patient will watch a Youtube compatible video of a child in the same age range as the study participants demonstrating proper brushing technique. The video will be paired with written subtitles created using the Social Story format. The subtitles will be read to the participant as the video plays. The patient will watch the video immediately before each brushing session morning and night for the three week intervention. After the intervention period the video will be made available on Youtube.com for the participants to use as they wish.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: video modeled social story
Description: Patient will watch a Youtube compatible video of a child in the same age range as the study participants demonstrating proper brushing technique. The video will be paired with written subtitles created using the Social Story format. The subtitles will be read to the participant as the video plays. The patient will watch the video immediately before each brushing session morning and night for the three week intervention. After the intervention period the video will be made available on Youtube.com for the participants to use as they wish.
Study: NCT06075524

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo blood and optional stool/tissue sample collection

Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Medical records are reviewed
Study: NCT04540679

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VIP4SCI
Description: Technology-enabled self-management \& rehabilitation solution

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VIP4SCI
Description: Technology-enabled self-management \& rehabilitation solution
Study: NCT00972049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2516
Description: Capsule administered once orally. Specific dose depends on dose panel.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule administered once orally
Study: NCT01300975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pentavalent antimony
Description: 3 intralesional injections of antimony at D1, D3 and D7

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cryotherapy
Description: Frozing of lesions with liquid nitrogen ad D1 and D14
Study: NCT04540679

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VIP4SCI
Description: Technology-enabled self-management \& rehabilitation solution
Study: NCT03837002

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: foot care protocol
Description: foot assesment, foot care, foot care education
Study: NCT02845193

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified Nasoalveolar molding
Description: Infants will receive this appliance which is a maxillary plate with nasal stent in addition to taping on the upper lip (taping is routine step in Grayson's nasoalveolar molding technique).
Study: NCT01300975

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo cream
Description: topical emollient crean 3 times a day during 21 days
Study: NCT00426829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/kg by vein every 14 days +/- 2 days, starting on day 1.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Radiation Therapy
Description: 3 Gy dose/fraction x 20 fractions.
Study: NCT02348632

Intervention type: DRUG
Group type: OTHER
Intervention: JZP-110
Study: NCT02845193

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Taping
Description: Infants will receive a tape only on the upper lip segments to mold it to touch each other.
Study: NCT04041544

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SN1011
Description: SN1011 will be supplied to the Pharmacy as 25 mg and 100 mg capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SN1011 placebo
Description: The placebo to be used in this study will be identical to SN1011, minus the active ingredient.
Study: NCT03148600

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor and bowel behavioural training
Description: Physiotherapist-led pelvic floor muscle and bowel behavioural training

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard arm
Description: Standard medical and nursing care
Study: NCT01158417

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol 40 mg oral three times a day
Description: Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol 500 mg oral once daily.
Description: Resveratrol 500 mg oral once daily.
Study: NCT01129414

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Omeprazole
Description: Pharmaceutical form: delayed-release capsule~Route of administration: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Omeprazole
Description: Pharmaceutical form: delayed-release capsule~Route of administration: oral
Study: NCT00949104

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sucrose
Description: 1 ml of 24% sucrose was administered 2 minutes prior to the procedure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Double distilled water
Description: 1 ml of double distilled water (Placebo) was administered 2 minutes prior to the procedure
Study: NCT04552067

Intervention type: DRUG
Group type: OTHER
Intervention: Lovenox
Description: patients given curative dose of Lovenox

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: patients given curative dose of Enoxa
Study: NCT04330989

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iNSC and Adherence supporter training
Description: Integrated next step counseling: iNSC is a structured, patient-centered approach informed by motivational interviewing techniques, which aims to foster an environment for joint-problem solving in order that the participant may identify their individual needs to increase or sustain sexual health through biomedical and non-biomedical approaches. iNSC frames the counselling sessions as a non-judgmental discussion to explore the facilitators and challenges to sexual health and medication adherence.~Adherence supporter training: Participants will be asked to identify a partner, family member, or friend to whom they are willing to disclose their HIV status (for HIV-positive women) or their intent to initiate PrEP (for HIV-negative women). Participants may also select a clinic-based peer to serve this adherence supporter role. Trainings will emphasize basic HIV knowledge, importance of antiretroviral adherence, potential drug side effects, and practical strategies for supporting adherence.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iNSC and Adherence supporter training
Description: Integrated next step counseling: iNSC is a structured, patient-centered approach informed by motivational interviewing techniques, which aims to foster an environment for joint-problem solving in order that the participant may identify their individual needs to increase or sustain sexual health through biomedical and non-biomedical approaches. iNSC frames the counselling sessions as a non-judgmental discussion to explore the facilitators and challenges to sexual health and medication adherence.~Adherence supporter training: Participants will be asked to identify a partner, family member, or friend to whom they are willing to disclose their HIV status (for HIV-positive women) or their intent to initiate PrEP (for HIV-negative women). Participants may also select a clinic-based peer to serve this adherence supporter role. Trainings will emphasize basic HIV knowledge, importance of antiretroviral adherence, potential drug side effects, and practical strategies for supporting adherence.
Study: NCT01803529

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: heat-pack with massage

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: heat-pack only
Study: NCT03824457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rheosorbilact®
Description: Rheosorbilact® is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of not more than 400 ml (6 to 7 ml/kg body weight per 24 hours) for 3 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer lactate
Description: Rheosorbilact® is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of not more than 400 ml (6 to 7 ml/kg body weight per 24 hours) for 3 days.
Study: NCT04347252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: Intravenous infusion of glucagon at fasting or elevated glycemia. Blockade of the GLP-1 receptor during hyperglycemia with and without glucagon.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: Intravenous infusion of glucagon at fasting or elevated glycemia. Blockade of the GLP-1 receptor during hyperglycemia with and without glucagon.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: Intravenous infusion of glucagon at fasting or elevated glycemia. Blockade of the GLP-1 receptor during hyperglycemia with and without glucagon.
Study: NCT00298311

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mci guidance peer support
Description: 12 weeks of home visits by peer mentor recovered from PPD and Keys to Caregiving (NCAST, 1990) program

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: mci guidance peer support
Description: 12 weeks of home visits by peer mentor recovered from PPD and Keys to Caregiving (NCAST, 1990) program
Study: NCT02159989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ziv-Aflibercept
Description: Given IV
Study: NCT03196973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DF289 plus DF277
Description: 1 vial into the affected ear twice daily for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DF289
Description: 1 vial into the affected ear twice daily for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DF277
Description: 1 vial into the affected ear twice daily for 7 days
Study: NCT03675594

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAD/CAM titanium denture base
Description: metallic denture base made of titanium

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAD/CAM cobalt/chromium denture bases
Description: metallic denture bases made of cobalt/chromium
Study: NCT02490904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone
Description: Double-blinded Eplerenone administered for 4 days at 25mg every 12 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Double-blinded Placebo administered for 4 days at 25mg every 12 hours
Study: NCT04124406

Intervention type: DEVICE
Intervention: Cologuard
Description: multi-target stool Deoxyribonucleic Acid (MT-sDNA) screening test
Study: NCT00673816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: Participants were expected to receive 9 months of sunitinib malate therapy administered in 6 cycles. Each cycle consisted of a daily oral dose of 50 mg sunitinib malate for 4 weeks followed by a 2-week rest period).